These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. Lv Q, Wang J, Xu C, Huang X, Ruan Z, Dai Y. Mol Med; 2020 May 24; 26(1):49. PubMed ID: 32448163 [Abstract] [Full Text] [Related]
4. Calycosin attenuates pulmonary fibrosis by the epithelial-mesenchymal transition repression upon inhibiting the AKT/GSK3β/β-catenin signaling pathway. Liu X, Shao Y, Zhang X, Ji X, Xie M, Liu H. Acta Histochem; 2021 Jul 24; 123(5):151746. PubMed ID: 34217047 [Abstract] [Full Text] [Related]
7. Dec1 Deficiency Ameliorates Pulmonary Fibrosis Through the PI3K/AKT/GSK-3β/β-Catenin Integrated Signaling Pathway. Hu X, Zou M, Ni L, Zhang M, Zheng W, Liu B, Cheng Z. Front Pharmacol; 2022 Jul 24; 13():829673. PubMed ID: 35355710 [Abstract] [Full Text] [Related]
12. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, Sortino MA, Nicoletti F, Copani A, Vancheri C. Pharmacol Res; 2008 Apr 24; 57(4):274-82. PubMed ID: 18346908 [Abstract] [Full Text] [Related]
19. Astragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Qian W, Cai X, Qian Q, Zhang W, Wang D. J Cell Mol Med; 2018 Sep 24; 22(9):4354-4365. PubMed ID: 29971947 [Abstract] [Full Text] [Related]
20. Honokiol inhibits epithelial-mesenchymal transition and hepatic fibrosis via activation of Ecadherin/GSK3β/JNK and inhibition of AKT/ERK/p38/β-catenin/TMPRSS4 signaling axis. Seo JH, Lee HJ, Sim DY, Park JE, Ahn CH, Park SY, Cho AR, Koo J, Shim BS, Kim B, Kim SH. Phytother Res; 2023 Sep 24; 37(9):4092-4101. PubMed ID: 37253375 [Abstract] [Full Text] [Related] Page: [Next] [New Search]